Eliem Therapeutics, Inc. announced that it has received $59.999987 million in funding from Intermediate Capital Group plc, RA Capital Management, L.P., Access Biotechnology, Samlyn Capital, LLC, Acorn Bioventures, LifeArc and other investors

On May 24, 2021, Eliem Therapeutics, Inc. closed the transaction. The series B round of funding co-led by RA Capital Nexus Fund II, L.P, a fund managed by returning investor RA Capital Management, L.P. and Intermediate Capital Group plc. The transaction also included participation from Samlyn Capital, LLC, Acorn Bioventures, LifeArc and returning investor Access Biotechnology and other investors.

RA Capital Management, L.P subscribed for 1,923,076 series B preferred shares of the issuer for an aggregate of $14,999,992.80. The company has raised $140,000,000 in funding till date. The company received $59,999,987 pursuant to exemption provided under Regulation D, from nine investors.